trilaciclib

cell-cycle inhibitor; FDA approved to mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer.

Also Known As:

2'-((5-(4-Methyl-1-piperazinyl)-2-pyridinyl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; cosela

Networked: 34 relevant articles (3 outcomes, 20 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - trilaciclib: 34
  - Pyrimidines: 510
    - trilaciclib: 34

Experts

1.	Antal, Joyce M: 5 articles (01/2021 - 11/2019)
2.	Morris, Shannon R: 5 articles (01/2021 - 11/2019)
3.	Malik, Rajesh K: 4 articles (10/2021 - 10/2020)
4.	Pritchett, Yili: 4 articles (01/2021 - 12/2020)
5.	Richards, Donald A: 3 articles (01/2022 - 11/2019)
6.	Xiao, Jie: 3 articles (01/2022 - 01/2021)
7.	Owonikoko, Taofeek K: 3 articles (01/2021 - 10/2020)
8.	Sorrentino, Jessica A: 3 articles (01/2021 - 10/2020)
9.	Horton, Janet K: 2 articles (08/2022 - 10/2021)
10.	Li, Chao: 2 articles (08/2022 - 01/2021)

Related Diseases

1.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 08/01/2022 - "Overall, the drug-drug interaction and safety profiles of trilaciclib in these studies support its continued use in patients with extensive-stage small-cell lung cancer. " 01/01/2021 - "We report integrated analyses of preclinical and clinical data that informed selection of the recommended Phase II dose (RP2D) used in trilaciclib trials in extensive-stage small cell lung cancer (ES-SCLC). " 01/01/2021 - "Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer." 01/01/2023 - "Trilaciclib is now approved as a myelopreservation agent in patients with extensive-stage small cell lung cancer. " 10/01/2021 - "Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer."
2.	Neutropenia 01/01/2021 - "Patients receiving trilaciclib had fewer grade ≥ 3 hematologic adverse events than patients receiving placebo, particularly neutropenia (75.0% versus 85.7%) and anemia (28.1% versus 60.7%). " 12/01/2022 - "In three studies of patients with extensive disease small cell lung cancer (ES-SCLC), trilaciclib reduced the severity and duration of neutropenia and thrombocytopenia as well as the need for blood transfusions. " 01/01/2023 - "In three randomized controlled phase II trials Trilaciclib proved effective in preventing neutropenia, thrombocytopenia and anemia in patients with non small cell lung cancer with non proficient RB1 gene. " 01/01/2023 - "In a pooled analysis of three randomized phase II studies of patients with small cell lung cancer, trilaciclib prevented neutropenia, thrombocytopenia, and anemia. " 04/01/2022 - "The use of trilaciclib was estimated to reduce the number of myelosuppressive AEs over a 5-year period (events avoided included 108 for neutropenia, 7 for febrile neutropenia, 23 for anemia, and 46 for thrombocytopenia) compared with the scenario without trilaciclib. "
3.	Triple Negative Breast Neoplasms 01/01/2022 - "Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study." 11/01/2019 - "Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial." 09/01/2023 - "Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer." 01/01/2023 - "This analysis aimed to characterize the population pharmacokinetics (PK) of trilaciclib, identify potential covariates influencing trilaciclib PK, and evaluate exposure-response relationships in extensive-stage small cell lung cancer (ES-SCLC) and triple-negative breast cancer (TNBC) trials. " 01/01/2023 - "Population pharmacokinetics and exposure-response of trilaciclib in extensive-stage small cell lung cancer and triple-negative breast cancer."
4.	Thrombocytopenia (Thrombopenia) 12/01/2022 - "In three studies of patients with extensive disease small cell lung cancer (ES-SCLC), trilaciclib reduced the severity and duration of neutropenia and thrombocytopenia as well as the need for blood transfusions. " 01/01/2023 - "In three randomized controlled phase II trials Trilaciclib proved effective in preventing neutropenia, thrombocytopenia and anemia in patients with non small cell lung cancer with non proficient RB1 gene. " 01/01/2023 - "In a pooled analysis of three randomized phase II studies of patients with small cell lung cancer, trilaciclib prevented neutropenia, thrombocytopenia, and anemia. " 04/01/2022 - "The use of trilaciclib was estimated to reduce the number of myelosuppressive AEs over a 5-year period (events avoided included 108 for neutropenia, 7 for febrile neutropenia, 23 for anemia, and 46 for thrombocytopenia) compared with the scenario without trilaciclib. " 11/01/2021 - "Administering trilaciclib prior to chemotherapy was associated with a reduction in neutropenia (82%), febrile neutropenia (75%), anemia (43%), and thrombocytopenia (96%) compared with chemotherapy alone. "
5.	Anemia 01/01/2023 - "Results showed that administration of Trilaciclib significantly reduced the occurrence of SN (19.3% vs. 42.2%, OR = 0.31), FN (3.22% vs. 6.72%, OR = 0.47), anemia (20.5% vs. 38.2%, OR = 0.38) and shortened the DSN during treatment. " 01/01/2021 - "Effects on RBC-related endpoints favored trilaciclib vs placebo, regardless of anemia risk factors and categories. " 01/01/2021 - "Patients receiving trilaciclib had fewer grade ≥ 3 hematologic adverse events than patients receiving placebo, particularly neutropenia (75.0% versus 85.7%) and anemia (28.1% versus 60.7%). " 01/01/2023 - "In three randomized controlled phase II trials Trilaciclib proved effective in preventing neutropenia, thrombocytopenia and anemia in patients with non small cell lung cancer with non proficient RB1 gene. " 01/01/2023 - "In a pooled analysis of three randomized phase II studies of patients with small cell lung cancer, trilaciclib prevented neutropenia, thrombocytopenia, and anemia. "

Related Drugs and Biologics

1.	Carboplatin (JM8)
2.	Gemcitabine
3.	Topotecan (Hycamtin)
4.	Etoposide (VP 16)
5.	Cyclin-Dependent Kinase 4
6.	atezolizumab
7.	Platinum
8.	Itraconazole (Sporanox)
9.	Rifampin (Rifampicin)
10.	Midazolam (Versed)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Immunotherapy
4.	Blood Transfusion (Blood Transfusions)
5.	Drug Tapering